Search results
Showing 1006 to 1020 of 1127 results for criteria
Learning disabilities and behaviour that challenges: service design and delivery (NG93)
This guideline covers services for children, young people and adults with a learning disability (or autism and a learning disability) and behaviour that challenges. It aims to promote a lifelong approach to supporting people and their families and carers, focusing on prevention and early intervention and minimising inpatient admissions.
This guideline covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It aims to improve ways of finding people who have TB in the community and recommends that everyone under 65 with latent TB should be treated. It describes how TB services should be organised, including the role of the TB control board.
Evidence-based recommendations on Memokath 051 Ureter stent for ureteric obstruction.
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment (HTG748)
Early value assessment (EVA) guidance on digital therapy for chronic tic disorders and Tourette syndrome.
Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)
Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.
Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments (TA1091)
Evidence-based recommendations on tarlatamab (IMDYLLTRA) for treating extensive-stage small-cell lung cancer after 2 or more treatments in adults.
Show all sections
Caris Molecular Intelligence for guiding cancer treatment (MIB120)
NICE has developed a medtech innovation briefing (MIB) on Caris Molecular Intelligence for guiding cancer treatment .
ColonFlag for identifying people at risk of colorectal cancer (MIB142)
NICE has developed a medtech innovation briefing (MIB) on ColonFlag for identifying people at risk of colorectal cancer .
Chronic wounds: advanced wound dressings and antimicrobial dressings (ESMPB2)
Summary of the evidence on advanced wound dressings and antimicrobial dressings for managing chronic wounds to inform local NHS planning and decision-making
Discontinued Reference number: GID-TA11289
Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under.
who are heterozygous for the CFTR mutations listed under the eligibility criteria for ivacaftor as a monotherapy in table 4 . b....
Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating chronic lymphocytic leukaemia in adults.
Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.
Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.